Note: The provided documents did not include a segment revenue table, and management explicitly avoided giving a precise FY27 top-line number. This summary sticks to what is verifiable from the presentation and concall.

Oriental Aromatics FY26: INR 1,000+ crore revenue, but margins under pressure

Oriental Aromatics reported a symbolic milestone in FY26: consolidated revenue from operations crossed the INR 1,000 crore mark. Revenue came in at INR 1,030.8 crore, up 11% year on year, helped by healthy demand across the company’s three verticals and steady volume momentum through the year.

But FY26 also highlighted how quickly profitability can compress when input costs spike and pricing remains tight. Consolidated EBITDA fell to INR 68.0 crore (from INR 93.4 crore in FY25) and EBITDA margin declined to 6.60%. Profit after tax dropped sharply to INR 3.2 crore, with PAT margin at just 0.31%.

Management’s explanation, repeated across the presentation and the earnings call, was consistent: a buyer’s market in aroma ingredients, all-time high terpene-linked inputs, firm crude-based raw materials, rupee depreciation, and the ramp-up drag from the Mahad facility.

Q4 FY26: Better quarter-on-quarter, but the full-year story remained tough

In Q4 FY26, the company delivered a clear quarter-on-quarter recovery. Consolidated revenue from operations was INR 282.4 crore, with EBITDA at INR 19.5 crore and PAT at INR 4.0 crore. EBITDA margin improved sequentially to 6.91% versus 5.25% in Q3 FY26.

However, the annual picture remained constrained. Full-year margins compressed meaningfully versus FY25, with expenses rising faster than revenue. Finance costs also increased in FY26, adding pressure as the company operated in an environment of raw material inflation and currency headwinds.

Operating context: volumes grew, but pricing and costs did not cooperate

Operationally, management reported healthy volume traction.

For FY26, total sales volume grew 9% over FY25, while total production volume increased 5% year on year. In Q4 FY26, sales volume grew 16% sequentially and 5% year on year.

Production volume in Q4 fell 7% sequentially and 14% year on year, which management attributed to lower production in the Specialty Chemicals division due to product mix changes and trial runs for new product intermediates.

A key detail from the concall was management’s description of the cost environment. They called it a “triple shock” across divisions:

1. Gum turpentine, CST and alpha-pinene prices rose and were said to be at all-time highs.

2. Crude-based inputs stayed volatile and firm, with some supply tightness.

3. Rupee depreciation increased the import cost portion of the raw material basket.

Management also described the global aroma ingredients market as a buyer’s market, with Chinese capacities continuing to supply non-tariff markets, keeping end-product pricing subdued.

Business structure: three divisions, roughly one-third each

When asked about segmental revenue, management did not provide a numeric split, but reiterated the company’s rule-of-thumb mix: Aroma Ingredients, Fragrance and Flavor, and Camphor and Terpene Chemicals typically contribute about one-third each (plus or minus a few percentage points).

The commentary also clarified where the pressure sits:

• In Fragrance and Flavor, the company saw healthy demand and customer additions, but the earlier benefit from softer key fragrance raw materials tapered off as inputs firmed up.

• In Aroma Ingredients, pricing stayed subdued due to oversupply dynamics, while raw material inflation and rupee depreciation hit costs.

• In Camphor and Terpene Chemicals, management highlighted a structural challenge: India has added substantial synthetic camphor capacity over the past few years, creating supply exceeding demand. Imports of natural camphor from China still influence pricing, though management said imports have reduced compared to the prior two years.

The company continues to focus on growing retail presence in camphor under the Saraswati and 3 Pine brands, along with strengthening B2B relationships.

Mahad ramp-up: strategic bet, near-term drag

Mahad remained the most important internal driver of margin discussion.

Management reiterated that Mahad is dragging consolidated EBITDA margin by about 1% to 1.5%. They said this drag was a key driver of the decline in consolidated net profit margin.

At the same time, they provided multiple signals of progress: sampling cycles with several global customers were completed, commercial shipments have commenced, and the business typically has a 6 to 9 month sample-to-commercial cycle. The company has also been qualified to submit bids for certain global RFQs for the second half of 2026.

On the financial side, management stated that Mahad can add about INR 60 to 65 crore of revenue at full utilization (discussed in response to analyst questions). They also discussed capex: around INR 90 crore invested including plot development and common infrastructure, with management clarifying that a portion relates to utilities that are expandable for future phases.

Importantly, management stated they expect the plant to reach 75% to 80% utilization in the next one year, at which point they expect it to become EBITDA neutral and then start contributing.

Capital allocation signals: dividend recommendation, but cash flow remains a watch item

The board recommended a final dividend of INR 0.50 per equity share for FY26, subject to shareholder approval.

However, cash flow metrics in the presentation were weak. FY26 cash flow from operations was INR 2.4 crore and free cash flow was negative. Alongside rising finance costs and higher net debt-to-equity, this is an area investors will likely track closely, especially if raw material volatility persists.

Takeaways from FY26

Oriental Aromatics finished FY26 with strong top-line growth and sustained volumes, but profitability was pressured by a combination of industry pricing dynamics, raw material inflation, currency depreciation, and the ramp-up drag from Mahad.

For FY27, management’s stated focus is consolidation and profit preservation: drive volumes, protect market share, accelerate Mahad’s commercial ramp-up, and rebuild margins through internal efficiency programs rather than relying on the pricing cycle to turn.

If Mahad ramps as planned and input inflation moderates, the company could see a more normalized margin profile. But management also cautioned that some headwinds may take a few quarters to work through, and that the worst may not yet be over on input-cost impact.